Synact Pharma Ab · OMXSTO:SYNACT
Synact Pharma Ab — Investor Presentation (September 2026)
26 slides from Synact Pharma Ab's investor presentation, September 2026
Slide 1: Treating Inflammation through Resolution Therapy
Treating Inflammation through Resolution Therapy Company Presentation September 2026
Slide 2: Disclaimer (1/3)
DISCLAIMER (1/3) This presentation and the information contained herein is strictly confidential and may not be referred to, quoted or otherwise disclosed by you, neither directly or indirectly nor wholly or partly. By receiving this information, you are acknowledging the confidential nature of this
Slide 3: Disclaimer (2/3)
DISCLAIMER (2/3) This Company Presentation may not be copied, passed on, reproduced, or redistributed, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person, and it may not be published anywhere, in whole or in part, for any purpose or under any circumstance
Slide 4: Disclaimer (3/3)
DISCLAIMER (3/3) In the United Kingdom, this Company Presentation is being made, and is directed only, to persons who are both: (i) qualified investors; and either (ii) persons falling within the definition of investment professionals (contained in article 19(5) of the Financial Services and Markets
Slide 5: Treating inflammation through pro-resolution therapy
Treating inflammation through pro-resolution therapy Pro-Resolution Resomelagon Synact Pharma Immunology (AP1189) Nasdaq Stockholm: SYNACT Immune resolution to First-in-class oral RA SEK 100m financing delay use of biologic treatment Phase 3- (Jul 2026) funds Phase immune suppressors ready 3 readine
Slide 6: Experienced management & board
Experienced management & board Jeppe Øvlesen Thomas Jonassen Ann Kristin Led Thomas Boesen Mads Bjerregaard MBA MD MSc PhD MSc CEO CSO & Co-founder CFO COO CBO 20+ yrs as CEO across Associate Professor, 20 years of international experience 20+ years of experience 20+ years of international biotech &
Slide 7: Broad pipeline with multiple upcoming milestones
Broad pipeline with multiple upcoming milestones Compound Indication Pre-Clinical Phase 1 Phase 2a Phase 2b Phase 3 Status & Milestones Phase 2 trials complete; supports Phase 3 Rheumatoid Arthritis (RA) Type-C FDA meetings Q4-26 Hyperinflammation in RESPIRE Phase 2a data mid 2027 severe respiratory
Slide 8: Pro-resolution: A differentiated approach to treating inflammation
Pro-resolution: A differentiated approach to treating inflammation Novel dual mechanism modulates macrophages and fibroblasts macrophage neutrophil macrophage Inflammation- resolving phenotype Pro-inflammatory fibroblast phenotype - Efferocytosis fibroblast - Phagocytosis - TNFα, IL-6, IL-1β - Proli
Slide 9: White space in rheumatoid arthritis (RA)
White space in rheumatoid arthritis (RA) Addressable market of 800,000 patients 1.8M diagnosed U.S. RA patients ~75% 1.35M Structurally open moderate- to-severe moderate-to-severe addressable market (SAM) No approved pre-biologic add-on to displace — entry defines the category A renewing annual pool
Slide 10: Patient journey in RA today: Majority require biologics within a year
Patient journey in RA today: Majority require biologics within a year Newly diagnosed — 1st line Progressive RA— 2nd/3rd line Biologic synthetic disease-modifying anti- Conventional synthetic disease-modifying anti- rheumatic drugs (bDMARDs) or JAK inhibitor rheumatic drugs (csDMARDs) Unmet need Met
Slide 11: Patient journey with resomelagon: Delayed progression to biologics
Patient journey with resomelagon: Delayed progression to biologics Newly diagnosed — 1st line Progressive RA— 2nd/3rd line Biologic synthetic disease-modifying anti- Conventional synthetic disease-modifying anti- rheumatic drugs (bDMARDs) or JAK inhibitor rheumatic drugs (csDMARDs) Resomelagon Metho
Slide 12: JAK / TNFa inhibitors set the efficacy bar but with serious risks and high cost
JAK / TNFa inhibitors set the efficacy bar but with serious risks and high cost Rinvoq (Abbvie) Olumiant (Eli Lilly) Enbrel (Amgen/Pfizer) SELECT EARLY RA-BEGIN TEMPO Arthritis & Rheumatology Vol. 72, No. 10, October 2020, pp 1607–1620 ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 3, March 2017, pp 506–517
Slide 13: The P2a BEGIN study
The P2a BEGIN study Demonstrated treatment effects in ACR response rates treatment-naïve RA patients at 4 weeks ACR20 ACR50 ACR70 70 60.6 * 60 100mg dose effective: (%)(%) 50 • Significant reduction in clinical activity disease index 37.9 Percentage 40 33.3 Percentage (CDAI) 30 24.2 20 13.3 12.1 • 6
Slide 14: The P2b EXPAND study
The P2b EXPAND study Effects seen in sub-group of patients with POST-HOC ANALYSIS IN PATIENTS WITH HIGH CRP, n=55 systemic inflammation at 12 weeks ACR response rates ACR20 ACR50 ACR70 • Demonstrated safety; efficacy endpoints not met Percentage (%) • Post-hoc analysis showed statistically significa
Slide 15: The P2b ADVANCE study
The P2b ADVANCE study Competitive efficacy observed on key secondary endpoint ACR response rates at week 12 76 On par with novel Percentage (%) • Demonstrated safety; primary efficacy endpoint not met biologics/JAKs • ACR20 on a par with novel biologics/JAKs (regulatory 38 endpoint for RA approvals)
Slide 16: P2b ADVANCE study post-hoc analysis
P2b ADVANCE study post-hoc analysis Significant treatment effect observed when patients with temporary flare-ups excluded Phase 3 design learning: Control for patients in flare-ups POST-HOC ANALYSIS EXCLUDING PATIENTS WITH TEMPORARY FLARE-UPS**, n=82 ACR response rates at week 12 ACR20 response over
Slide 17: Resomelagon safety and tolerability support first line use
Phase 2b ADVANCE study Resomelagon safety and tolerability support first line use Resomelagon Resomelagon Resomelagon Placebo 40 mg 70 mg 100 mg + MTX + MTX + MTX + MTX • Benign safety profile with no n=59 n=64 n=62 n=61 SAEs, few mostly transient 14 reported 17 reported 16 reported 25 reported AEs,
Slide 18: Supports progression to phase 3 and broader potential in inflammatory diseases
Phase 2b ADVANCE study Supports progression to phase 3 and broader potential in inflammatory diseases INSIGHTS FOR PHASE 3 SIGNIFICANT EFFECT ON KEY INFLAMMATION MARKERS • Design for ACR response ACR20 and ACR50 • Design for stabilized hsCRP mg/L background response (screen out flares) • Dosing 40mg
Slide 19: Why infectious disease?
Why infectious disease? • Hyperinflammation (due to certain infections) leads to poor outcomes in infectious diseases STATUS OF STUDIES IN INFECTIOUS DISEASE • Hyperinflammation takes different forms in different types of infection • RESOVIR-1 Hospitalized Covid-19 patients Results reported demonstr
Slide 20: First demonstration of effects of pro-resolving drug in context of severe infection
RESOVIR-1 Study in COVID-19 patients First demonstration of effects of pro-resolving drug in context of severe infection Significantly shorter time to respiratory recovery • Significantly reduced time to respiratory recovery, and discharge in COVID-19 patients time to discharge and time in ICU 10 9
Slide 21: P2a RESOVIR-2 study in Dengue Virus
P2a RESOVIR-2 study in Dengue Virus Hipolabor 50/50 co-development and profit share in Brazil (term sheet signed) UNMET NEED: • ~400 million people are infected1 • 100 million become ill1 • 13,500 – 40,000 deaths attributed to dengue2 Double-blind randomized placebo- controlled study • 120 patients
Slide 22: P2a RESPIRE study in severe respiratory infections
P2a RESPIRE study in severe respiratory infections >2M US hospital admissions annually from respiratory viral infections US NIAID vision: Double-blind randomized placebo-controlled Focus on host directed therapies study • 96 patients randomized 1:1 • Once daily resomelagon (100mg) or placebo over 14
Slide 23: Multiple upcoming milestones
Multiple upcoming milestones Q3 Q4 Q1 Q2 Q3 Q4 Milestone 2026 2026 2027 2027 2027 2027 SEK 100m convertible facility supports runway and Phase 3 readiness Pivotal program preparation building on ADVANCE - 40 mg dose selected Regulatory feedback on the Phase 3 clinical development from FDA and EMA De
Slide 24: Multiple Layers of Protection
Multiple Layers of Protection CoM Crystal Form Asset in Development US Patents 12,239,631 & 12,661,336 CoM Formulation Composition of matter patents covering the polymorphic form of the resomelagon salt employed in the clinic Use Resomelagon + MTX Extend exclusivity from 2042 until July 2044 in the
Slide 25: Key Financials and Shareholder Structure
Key Financials and Shareholder Structure KEY FINANCIALS (H1 2026 / Q2 2026) SHAREHOLDER STRUCTURE 5% SEK 14.3 M SEK 55.1 M SEK 47.5 M Cash & Cash Equivalents H1 2026 Operating Expenses H1 2026 Net Loss As of 30 June 2026 -6% YoY Vs. SEK 52.2M H1 2025 40% 55% 82% Q3 2027 56.2 M Equity / Asset Ratio C
Slide 26: SynAct Pharma - Investment Thesis
SynAct Pharma - Investment Thesis U N MET C OM PELLI NG PA TH TO NEED BI OLO GY VALU E Large & Resomelagon First-in-Class Underserved Multiple Near-Term Mechanism Market Catalysts • Majority of newly • Resomelagon reduces • Type C FDA meeting Q4 diagnosed patients inflammation and 2026 - P3-ready ne
SynAct Pharma — Investor Presentation (September 2026) on 6ix